MSD has announced the
TGA approval of its biosimilar
Brenzys (etanercept) for the
treatment of rheumatoid arthritis,
spondyloarthritis, psoriatic arthritis
and psoriasis in adults aged over 18.
The next step is a potential
listing on the Pharmaceutical
Benefits Scheme, with Brenzis
set to possibly become the first
immunology biosimilar dispensed
via community pharmacy because
if the product is ‘a’-flagged by the
PBAC, pharmacists will be able to
substitute the product without
reference to the prescriber, said
MSD medical director Dr Gary
Jankelowitz.
Brenzys has also been approved
for marketing in Korea (PD 27 Jul).The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jul 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.